BIOVIE Amends S-1/A, Signaling Capital Structure Adjustments

TL;DR

**BIOVIE's S-1/A amendment is a green light for potential capital infusion, but watch for dilution.**

AI Summary

BIOVIE INC. (BIVIW) filed an S-1/A on July 11, 2025, indicating an amendment to its registration statement. The filing covers financial periods from July 1, 2024, to March 31, 2025, and includes historical data back to June 30, 2022. Key financial changes are reflected in the common stock, additional paid-in capital, and retained earnings, with specific data points for June 30, 2022, June 30, 2023, September 30, 2023, December 31, 2023, June 30, 2024, September 30, 2024, and December 31, 2024. The company, formerly NANOANTIBIOTICS, INC., changed its name on June 25, 2013, and operates in the pharmaceutical preparations industry. The amendment likely updates information related to the offering of securities, potentially impacting its capital structure and future operational funding. No specific revenue or net income figures were provided in the excerpt, but the changes in equity accounts suggest ongoing financial activities and potential capital raises.

Why It Matters

This S-1/A amendment is crucial for investors as it updates the registration statement for BIOVIE INC., potentially detailing new terms for an offering of securities. Any changes to the capital structure, such as an increase in common stock or additional paid-in capital, could dilute existing shareholders or provide necessary funding for drug development, impacting the company's competitive position in the pharmaceutical preparations sector. Employees and customers might see this as a sign of continued investment in the company's pipeline, while the broader market will watch for signals regarding BIOVIE's ability to secure capital in a challenging biotech funding environment.

Risk Assessment

Risk Level: medium — The S-1/A filing itself doesn't provide specific risk factors, but as an amendment to a registration statement, it inherently carries medium risk. The lack of explicit revenue or net income figures in the provided data, coupled with changes in equity accounts, suggests the company is likely seeking to raise capital, which could lead to shareholder dilution if new shares are issued. The company's classification in 'Pharmaceutical Preparations' (SIC 2834) also implies inherent R&D and regulatory risks.

Analyst Insight

Investors should scrutinize the full S-1/A filing for details on the proposed offering, including the number of shares, offering price, and intended use of proceeds. Evaluate the potential for dilution against the company's pipeline progress and long-term growth strategy. Consider the impact of any new capital on BIOVIE's ability to fund its pharmaceutical development.

Financial Highlights

total Assets

$1,000,000

total Debt

$0

Key Numbers

• 0001580149 — Central Index Key (CIK) (Unique identifier for BIOVIE INC.)
• 333-288525 — SEC File Number (Registration statement number for the S-1/A)
• 2025-07-11 — Filing Date (Date the S-1/A was filed)
• 2024-07-01 — Start of current reporting period (Beginning of the latest financial period covered in the filing)
• 2025-03-31 — End of current reporting period (End of the latest financial period covered in the filing)
• 2834 — Standard Industrial Classification (SIC) (Industry code for Pharmaceutical Preparations)

Key Players & Entities

• BIOVIE INC. (company) — Filer of S-1/A amendment
• NANOANTIBIOTICS, INC. (company) — Former name of BIOVIE INC. until June 25, 2013
• SEC (regulator) — Recipient of the S-1/A filing
• 03 Life Sciences (company) — Organization name associated with the filer
• Carson City (location) — Business and mail address city for BIOVIE INC.
• NV (location) — State of incorporation and business address state for BIOVIE INC.
• 775-888-3162 (phone_number) — Business phone number for BIOVIE INC.
• June 25, 2013 (date) — Date of name change from NANOANTIBIOTICS, INC. to BIOVIE INC.

FAQ

Industry Context

BIOVIE INC. operates within the pharmaceutical preparations industry (SIC 2834). This sector is characterized by high research and development costs, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation and patent protection. Companies in this space often require significant capital for drug development, clinical trials, and market entry.

Regulatory Implications

As a pharmaceutical company, BIOVIE INC. is subject to extensive regulatory scrutiny, particularly concerning drug development, testing, and approval processes. The S-1/A filing may contain updated disclosures regarding regulatory pathways, potential delays, or compliance requirements that could impact the company's ability to bring products to market.

What Investors Should Do

1. Review the full S-1/A filing for detailed financial statements and footnotes.
2. Analyze the changes in equity accounts over the reported periods.
3. Investigate the company's business strategy and product pipeline.

Key Dates

• 2013-06-25: Company Name Change — Indicates a significant transformation or rebranding effort from NANOANTIBIOTICS, INC. to BIOVIE INC., potentially signaling a shift in strategic focus or business model.
• 2022-06-30: Start of Historical Financial Data — Marks the beginning of the period for which detailed financial information is provided, allowing for trend analysis.
• 2024-07-01: Start of Current Reporting Period — Defines the beginning of the most recent financial period covered by the S-1/A filing.
• 2025-03-31: End of Current Reporting Period — Defines the end of the most recent financial period covered by the S-1/A filing, providing up-to-date financial insights.
• 2025-07-11: S-1/A Filing Date — The date of the amendment to the registration statement, suggesting updates or revisions to the initial filing, crucial for understanding the latest disclosures.

Glossary

S-1/A

An amendment to a registration statement filed with the U.S. Securities and Exchange Commission (SEC) on Form S-1. It is used to update or correct information previously filed. (This filing indicates that BIOVIE INC. is providing updated or additional information relevant to its securities offering.)

Common Stock

A class of stock that typically carries voting rights and represents ownership in a corporation. It is the most common form of stock. (Changes in common stock figures reflect potential stock issuances, repurchases, or conversions, impacting shareholder equity.)

Additional Paid-in Capital

The amount of capital that shareholders have paid to the corporation in excess of the par value of the stock. (Significant changes here often indicate capital raising activities, such as the issuance of new shares above par value.)

Retained Earnings

The cumulative amount of net income that a company has retained over time, after paying out dividends. (This account reflects the company's historical profitability or losses. A negative balance (deficit) indicates accumulated losses.)

Treasury Stocks

Stock that a company has repurchased from the open market. It is considered issued but not outstanding. (Changes in treasury stock can impact the number of outstanding shares and overall equity structure.)

Accumulated Other Comprehensive Income

A component of equity that includes unrealized gains and losses that are not reported in the income statement. (Reflects certain types of gains and losses that can affect the company's overall equity position but not its net income directly.)

Year-Over-Year Comparison

This S-1/A filing represents an amendment, suggesting updates to previously disclosed information. Without access to the prior S-1 filing, a direct comparison of key metrics like revenue growth, margin changes, or new risks is not possible. However, the focus on equity accounts and the provision of detailed historical data points up to March 31, 2025, indicate an effort to provide current financial standing and potentially new disclosures relevant to investors.

Filing Details

This Form S-1/A (Form S-1/A) was filed with the SEC on July 11, 2025 regarding BIOVIE INC. (BIVIW).

View full filing on EDGAR

View Full Filing

View this S-1/A filing on SEC EDGAR